Abstract
Objectives We analysed mortality rates in a nonmetropolitan UK subregion (Northamptonshire) to understand SARSCoV2 disease fatalities at sub 1,000,000 population levels. A numerical (SEIR) model was then developed to predict the spread of Covid19 in Northamptonshire.
Methods A combined approach using statistically-weighted data to fit the start of the epidemic to the mortality record. Parameter estimates were then derived for the transmission rate and basic reproduction number.
Results Age standardised mortality rates are highest in Northampton (urban) and lowest in semi-rural districts. Northamptonshire has a statistically higher Covid-19 mortality rate than for the East Midlands and England as a whole. Model outputs suggest the number of infected individuals exceed official estimates, meaning less than 40% of the population may require immunisation.
Conclusions Combining published (sub-regional) mortality rate data with deterministic models on disease spread has the potential to help public health practitioners develop bespoke mitigations, guided by local population demographics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used are Open Source data, anonymised and available without constraint from the UK Office for National Statistics, London
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.